BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Glecirasib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Glecirasib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06008288-2045@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glecirasib: Phase 2 readout est. (NCT06008288)
DESCRIPTION:Glecirasib\, phase 2.\nStudy: A Phase II Study Evaluating JAB-2
 1822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid 
 Tumors Harboring the KRAS p.G12C Mutation.\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gle
 cirasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06008288
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05288205-2045@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT05288205)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid 
 Tumors Harboring KRAS p.G12C Mutation\nEstimated primary completion: March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0528820
 5
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05276726-2045@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT05276726)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and ST
 K11 Co-mutation and Wild-type KEAP1\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05276726
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339839-2045@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT07339839)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Gl
 ecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-m
 utated NSCLC\nEstimated primary completion: 30 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/glecirasib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07339839
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2045@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Glecirasib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Glecirasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harb
 oring Rare Mutations.\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827261-2045@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Glecirasib: Phase 2 readout est. (NCT07827261)
DESCRIPTION:Glecirasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutate
 d Locally Advanced or Metastatic Non-Small Cell Lung Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/glecirasib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07827261
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164170-2045@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Glecirasib: Phase 2 readout est. (NCT07164170)
DESCRIPTION:Glecirasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib\nE
 stimated primary completion: 30 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/glecirasib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07164170
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06416410-2045@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Glecirasib: Phase 3 readout est. (NCT06416410)
DESCRIPTION:Glecirasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JAB-
 21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment 
 of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation\nEstimate
 d primary completion: 30 September 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/glecirasib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06416410
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
